Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.